Ginkgo Results Presentation Deck

Biosecurity Highlights (Unaudited) 0 $ 22 -10% Biosecurity Revenue ($M) Q1 2021 $22 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 $43 22% Q2 2021 Biosecurity Gross Margin $ 114 48% Q3 2021 $147 42% 42% Q4 2021 Q1 2022 $100 Q2 2022 36% Q2 2022 Concentric's pathogen monitoring network has delivered testing across most of the U.S.) Demonstrated ability to deliver testing in diverse jurisdictions States in which Concentric has delivered testing services Airport testing locations *Map shading reflects all states in which Concentric has delivered testing since launching in 2020, not all states currently have active testing programs. Breadth is important given diverse set of state operating models. 10.3 million+ Samples to date 37,000+ Viral samples sequenced to date 5,400+ Organizations supported to date 4 Key US airports Data updated 08/01/22 Continuing to diversify biosecurity business through new initiatives including passive air and wastewater monitoring New contract with CDC for ongoing inbound air travel monitoring supports our belief that biosecurity is here to stay and that Ginkgo has the opportunity to play a leading role 11 Property of Ginkgo Bioworks Q2 2022 UPDATE & BUSINESS REVIEW

View entire presentation